About: Can Nebulised Heparin Reduce Time to Extubation in SARS CoV 2 The CHARTER Study Protocol

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Can Nebulised Heparin Reduce Time to Extubation in SARS CoV 2 The CHARTER Study Protocol Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Can Nebulised Heparin Reduce Time to Extubation in SARS CoV 2 The CHARTER Study Protocol
Creator	Artigas, Antonio Dixon, Barry Doig, Gordon Laffey, John Moran, John Prof, A Santamaria, John Smith, J Skidmore, Mark Gupta, Sachin Mcnicholas, Bairbre Andrade De Lima, Marcelo Ghosh, Angajendra Nunes, Mr Roger, Mr Said, Ms Schmidt, Eric Vanharen, Frank
Source	MedRxiv
abstract	Introduction: COVID 19 is associated with the development of ARDS displaying the typical features of diffuse alveolar damage with extensive pulmonary coagulation activation resulting in fibrin deposition in the microvasculature and formation of hyaline membranes in the air sacs. The anticoagulant actions of nebulised heparin limit fibrin deposition and progression of lung injury. Serendipitously, unfractionated heparin also inactivates the SARS CoV 2 virus and prevents its entry into mammalian cells. Nebulisation of heparin may therefore limit both fibrin mediated lung injury and inhibit pulmonary infection by SARS CoV 2. For these reasons we have initiated a multicentre international trial of nebulised heparin in patients with COVID 19. Methods and intervention: Mechanically ventilated patients with confirmed or strongly suspected SARS CoV 2 infection, hypoxaemia and an acute pulmonary opacity in at least one lung quadrant on chest Xray, will be randomised to nebulised heparin 25,000 Units every 6 hours or standard care for up to 10 days while mechanically ventilated. The primary outcome is the time to separation from invasive ventilation to day 28, where non survivors to day 28 are treated as though not separated from invasive ventilation. Ethics and dissemination: The study protocol has been submitted to the human research and ethics committee of St Vincents Hospital, Melbourne, Australia. Submission is pending in other jurisdictions. Results of this study will be published in scientific journals and presented at scientific meetings.
has issue date	2020-05-01(xsd:dateTime)
bibo:doi	10.1101/2020.04.28.20082552
has license	medrxiv
sha1sum (hex)	97306f669a1cd60836e6765aa7748ae960c26e5a
schema:url	https://doi.org/10.1101/2020.04.28.20082552
resource representing a document's title	Can Nebulised Heparin Reduce Time to Extubation in SARS CoV 2 The CHARTER Study Protocol
resource representing a document's body	covid:97306f669a1cd60836e6765aa7748ae960c26e5a#body_text
is schema:about of	named entity 'RESULTING IN' named entity 'DIFFUSE ALVEOLAR DAMAGE' named entity 'PULMONARY INFECTION' named entity 'ARDS' named entity 'nebulised' named entity 'progression' named entity 'heparin' named entity 'nebulised' named entity 'pulmonary' named entity 'COVID-19' named entity 'pulmonary infection' named entity 'hyaline' named entity 'SARS-CoV-2' named entity 'unfractionated heparin' named entity 'heparin' named entity 'COVID-19' named entity 'Extubation' named entity 'Nebulised' named entity 'physical function' named entity 'heparin' named entity 'budesonide' named entity 'fibrin' named entity 'ritonavir' named entity 'HFOV' named entity 'ARDS' named entity 'subcutaneously' named entity 'Nebulised' named entity 'vasopressor' named entity 'heparin' named entity 'ICU' named entity 'coagulation factors' named entity 'haemoptysis' named entity 'external environment' named entity 'antifungal' named entity 'neuromuscular blocker' named entity 'cardiac surgery' named entity 'intensive care' named entity 'peramivir' named entity 'blood test results' named entity 'COVID-19' named entity 'red cells' named entity 'endotracheal tube' named entity 'medRxiv' named entity 'intravenous' named entity 'respiratory rate' named entity 'red cells' named entity 'biopsies' named entity 'thrombosis' named entity 'Heparin' named entity 'antifungal' named entity 'medRxiv' named entity 'health records' named entity 'long term' named entity 'SARS-CoV-2' named entity 'transfusion' named entity 'heparin' named entity 'Intensive Care' named entity 'medRxiv' named entity 'nebulised' named entity 'heparin' named entity 'histological' named entity 'intensive care' named entity 'CC-BY 4.0 International license' named entity 'unfractionated heparin' named entity 'humidifier' named entity 'haemoglobin' named entity 'sepsis' named entity 'ventilator'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software